VerImmune Completes $4.5 Million First Closing of Pre-Series A Financing, Strengthens Board with Two Accomplished Biotechnology Executives

BETHESDA, Md. and SINGAPORE, Sept. 23, 2024 /PRNewswire/ — VerImmune Inc., (“VerImmune”), a venture-backed biotechnology company developing a groundbreaking Virus-inspired Particle (ViP™) platform technology, today announced the successful first closing of $4.5 million in its Pre-Series…